N- (4- ((5- (hydroxy(phenyl)methyl)pyrrolidin- 2- yl)methyl)phenyl)- 4- oxo- 4,6,7,8- tetrahydropyrrolo(1,2- a)pyrimidine- 6- carboxamide

01/01/2018 - "Long-term (52-week) treatment with vibegron is safe, well-tolerated and effective in patients with overactive bladder."
01/01/2023 - "The EMPOWUR study was a phase 3 clinical trial that looked at whether vibegron was safe and improved symptoms in people with overactive bladder. "
11/01/2021 - "The use of vibegron for overactive bladder (OAB) was effective and safe in pivotal clinical trials. "
10/01/2022 - "Re: Urodynamic evaluation of the efficacy of vibegron, a new β3-adrenergic receptor agonist, on lower urinary tract function in children and adolescents with overactive bladder."
10/01/2022 - "Urodynamic evaluation of the efficacy of vibegron, a new β3-adrenergic receptor agonist, on lower urinary tract function in children and adolescents with overactive bladder."

06/01/2023 - "Patients who took daily vibegron had significant improvements over the placebo group in both primary and secondary endpoints, except for daily nocturia episodes. "
01/01/2019 - "Efficacy of novel β3 -adrenoreceptor agonist vibegron on nocturia in patients with overactive bladder: A post-hoc analysis of a randomized, double-blind, placebo-controlled phase 3 study."
01/01/2019 - "Editorial Comment to Efficacy of novel β3 -adrenoreceptor agonist vibegron on nocturia in patients with overactive bladder: A post-hoc analysis of a randomized, double-blind, placebo-controlled phase 3 study."
01/01/2019 - "To investigate the efficacy of vibegron on nocturia in patients with overactive bladder. "
01/01/2019 - "Among the Japanese overactive bladder patients enrolled in the placebo-controlled, multicenter, randomized, double-blind phase 3 study of vibegron, a total of 669 patients with nocturia (≥1 nocturnal void) were included. "

11/01/2020 - "Effects of a new β3-adrenoceptor agonist, vibegron, on neurogenic bladder dysfunction and remodeling in mice with spinal cord injury."
02/18/2021 - "Vibegron improved the urodynamic parameters for anticholinergic-resistant neurogenic bladder. "
01/01/2022 - "Favorable efficacy of vibegron for antimuscarinic-resistant neurogenic bladder dysfunction due to spina bifida was shown video-urodynamically without apparent adverse events. "
01/01/2022 - "In this retrospective study, 15 patients with antimuscarinic-resistant neurogenic bladder dysfunction due to spina bifida underwent a video-urodynamic study before and during the administration of vibegron 50 mg once daily instead of antimuscarinic agents from February 2019 through April 2021. "
01/01/2022 - "Editorial Comment to Video-urodynamic effects of vibegron, a new selective β3-adrenoceptor agonist, on antimuscarinic-resistant neurogenic bladder dysfunction in patients with spina bifida."

12/01/2020 - "Re: Efficacy of the novel selective β3-adrenoreceptor agonist vibegron for treatment-resistant monosymptomatic nocturnal enuresis in children."
08/01/2020 - "Efficacy of the novel selective β3-adrenoreceptor agonist vibegron for treatment-resistant monosymptomatic nocturnal enuresis in children."
01/01/2023 - "This study evaluated the short-term effectiveness and safety of vibegron (50 mg) for children with refractory nocturnal enuresis. "
01/01/2023 - "Effects of short-term treatment with vibegron for refractory nocturnal enuresis."

01/01/2023 - "Short-term treatment with vibegron is safe and effective for children with refractory enuresis."
01/01/2023 - "Enuresis frequency was recorded during 30 days before and after additional vibegron administration with prior treatment. "
01/01/2023 - "Enuresis frequencies (mean ± standard deviation [SD]) were, respectively, 15.8 ± 9.2 and 9.5 ± 9.6 before and after treatment with vibegron during the observed 30 days. "
01/01/2023 - "We assessed the treatment effectiveness based on enuresis frequencies between before and after treatment with vibegron 50 mg. "
01/01/2023 - "Combination treatment with vibegron and solifenacin for refractory non-monosymptomatic enuresis."